Clinical Implementation of 177 Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

[摘要] In March 2022, 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan)received Food and Drug Administration approval for treatment ofmetastatic castration-resistant prostate cancer (mCRPC) in men withprostate-specific membrane antigen (PSMA)–avid disease who havereceived prior chemotherapy and a novel androgen receptor–directed therapy (1). Approval followed the VISION trial, whichdemonstrated a median 4-mo overall survival benefit for 177LuPSMA-617 plus best supportive care versus best supportive carealone (2). 177Lu-PSMA-617 is the first theranostic agent for prostate cancer and a clinically meaningful addition to the therapeuticarmamentarium. Here, we describe the process of clinical implementation of 177Lu-PSMA-617 at a major academic center,highlighting successes and challenges.

[学科分类] 医学（综合）